Kalaris Therapeutics, Inc. — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allovir, Inc. (ALVR)
CIK: 0001754068
Period of Report: 2021-03-01

Reporting Person: Leen Ann M. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	S	6359	$38.4607	Disposed	2465326	Indirect
2021-03-01	Common Stock	S	3159	$39.1762	Disposed	2462167	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	28000	Direct

Footnotes

F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.89 to $38.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.